These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 7297027)

  • 1. Reduced verapamil clearance during long-term oral administration.
    Shand DG; Hammill SC; Aanonsen L; Pritchett EL
    Clin Pharmacol Ther; 1981 Nov; 30(5):701-6. PubMed ID: 7297027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolongation of verapamil elimination kinetics during chronic oral administration.
    Schwartz JB; Keefe DL; Kirsten E; Kates RE; Harrison DC
    Am Heart J; 1982 Aug; 104(2 Pt 1):198-203. PubMed ID: 7102502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An investigation of the cause of accumulation of verapamil during regular dosing in patients.
    Schwartz JB; Abernethy DR; Taylor AA; Mitchell JR
    Br J Clin Pharmacol; 1985 Apr; 19(4):512-6. PubMed ID: 3994898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Opposite effect of diabetes mellitus induced by streptozotocin on oral and intravenous pharmacokinetics of verapamil in rats.
    Hu N; Xie S; Liu L; Wang X; Pan X; Chen G; Zhang L; Liu H; Liu X; Liu X; Xie L; Wang G
    Drug Metab Dispos; 2011 Mar; 39(3):419-25. PubMed ID: 21135265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Verapamil and norverapamil plasma levels in infants and children during chronic oral treatment.
    Piovan D; Padrini R; Svalato Moreolo G; Magnolfi G; Milanesi O; Zordan R; Pellegrino PA; Ferrari M
    Ther Drug Monit; 1995 Feb; 17(1):60-7. PubMed ID: 7725379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Verapamil kinetics in normal subjects and patients with coronary artery spasm.
    Freedman SB; Richmond DR; Ashley JJ; Kelly DT
    Clin Pharmacol Ther; 1981 Nov; 30(5):644-52. PubMed ID: 7297023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Verapamil disposition kinetics in chronic atrial fibrillation.
    Kates RE; Keefe DL; Schwartz J; Harapat S; Kirsten EB; Harrison DC
    Clin Pharmacol Ther; 1981 Jul; 30(1):44-51. PubMed ID: 7237897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Faster clearance of sustained release verapamil in men versus women: continuing observations on sex-specific differences after oral administration of verapamil.
    Krecic-Shepard ME; Barnas CR; Slimko J; Schwartz JB
    Clin Pharmacol Ther; 2000 Sep; 68(3):286-92. PubMed ID: 11014410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo comparison of putative probes of CYP3A4/5 activity: erythromycin, dextromethorphan, and verapamil.
    Krecic-Shepard ME; Barnas CR; Slimko J; Gorski JC; Wainer IW; Schwartz JB
    Clin Pharmacol Ther; 1999 Jul; 66(1):40-50. PubMed ID: 10430108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of steady-state verapamil plasma concentrations in children and adults.
    Wagner JG; Rocchini AP; Vasiliades J
    Clin Pharmacol Ther; 1982 Aug; 32(2):172-81. PubMed ID: 7094504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of verapamil in patients with hypertension.
    Anderson P; Bondesson U; de Faire U
    Eur J Clin Pharmacol; 1986; 31(2):155-63. PubMed ID: 3803414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of verapamil and norverapamil during long-term oral therapy.
    Tartaglione TA; Pieper JA; Lopez LL; Mehta J
    Res Commun Chem Pathol Pharmacol; 1983 Apr; 40(1):15-27. PubMed ID: 6867470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Verapamil and norverapamil in plasma and breast milk during breast feeding.
    Anderson P; Bondesson U; Mattiasson I; Johansson BW
    Eur J Clin Pharmacol; 1987; 31(5):625-7. PubMed ID: 3830249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of naringin on the pharmacokinetics of verapamil and one of its metabolites, norverapamil, in rabbits.
    Kim HJ; Choi JS
    Biopharm Drug Dispos; 2005 Oct; 26(7):295-300. PubMed ID: 16013069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of verapamil and its metabolite norverapamil in rats with hyperlipidaemia induced by poloxamer 407.
    Lee YS; Yoon JN; Yoon IS; Lee MG; Kang HE
    Xenobiotica; 2012 Aug; 42(8):766-74. PubMed ID: 22300394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Verapamil metabolite exposure in older and younger men during steady-state oral verapamil administration.
    Abernethy DR; Wainer IW; Anacleto AI
    Drug Metab Dispos; 2000 Jul; 28(7):760-5. PubMed ID: 10859149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of sustained-release verapamil after a single administration and at steady state.
    Mattila J; Mäntylä R; Taskinen J; Männistö P
    Eur J Drug Metab Pharmacokinet; 1985; 10(2):133-8. PubMed ID: 3840089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of gender on the pharmacokinetics of verapamil and norverapamil in human.
    Dadashzadeh S; Javadian B; Sadeghian S
    Biopharm Drug Dispos; 2006 Oct; 27(7):329-34. PubMed ID: 16892180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pharmacology of verapamil. IV. Kinetic and dynamic effects after single intravenous and oral doses.
    McAllister RG; Kirsten EB
    Clin Pharmacol Ther; 1982 Apr; 31(4):418-26. PubMed ID: 7060323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Verapamil disposition and cardiovascular effects in elderly patients after single intravenous and oral doses.
    Carosella L; Menichelli P; Alimenti M; Zuccala G; Gemma A; Cocchi A; Carbonin PU
    Cardiovasc Drugs Ther; 1989 Jun; 3(3):417-25. PubMed ID: 2487538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.